Literature DB >> 2004475

Long-term follow-up of treatment of thyrotoxicosis by three different methods.

J A Franklyn1, J Daykin, Z Drolc, M Farmer, M C Sheppard.   

Abstract

In view of continuing debate regarding the best definitive therapy for thyrotoxicosis, we examined the long-term outcome of radioiodine (131I) or surgical treatment of 1918 thyrotoxic patients divided into three groups: those given 131I at a dose calculated from thyroid size, 131I uptake and effective half-life to administer a fixed radioactivity dose to the thyroid; those treated with a dose of 131I (110, 185 or 370 MBq) chosen empirically; and those treated by partial thyroidectomy. A minimum 10-year follow-up was achieved for 1119 patients treated with a calculated 131I dose; a single dose resulted in control of disease in 90.5%. At 5 years, 18% were hypothyroid, the prevalence rising to 42% at 20 years. Of 504 patients treated with an empirical 131I dose and followed for at least 5 years, thyrotoxicosis was controlled by a single dose in 89.7%. The rate of hypothyroidism at 5 years (38.5%) was higher than that found in the calculated dose group. A minimum 10-year follow-up was achieved for 295 surgically treated patients; thyrotoxicosis was controlled in 89.2%. The prevalence of hypothyroidism (2% at 5 years, 27.5% at 20 years) was lower than that found after 131I, whether given by calculated or empirical dose. Each of the treatments employed resulted in an acceptable rate of cure of thyrotoxicosis. If maintenance of euthyroidism is the major objective, our findings suggest that surgery represents the treatment of choice. Furthermore, calculated dose 131I administration has advantages in terms of risk of hypothyroidism over empirical dose treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004475     DOI: 10.1111/j.1365-2265.1991.tb01738.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  25 in total

1.  Radioiodine for hyperthyroidism.

Authors:  J Franklyn; M Sheppard
Journal:  BMJ       Date:  1992-09-26

2.  Safety of long-term antithyroid drug treatment? A systematic review.

Authors:  F Azizi; R Malboosbaf
Journal:  J Endocrinol Invest       Date:  2019-05-27       Impact factor: 4.256

3.  Graves' thyrotoxicosis and coronary artery spasm.

Authors:  R A Chudleigh; J S Davies
Journal:  Postgrad Med J       Date:  2007-11       Impact factor: 2.401

4.  Treatment of hyperthyroidism in young people.

Authors:  T D Cheetham; I A Hughes; N D Barnes; E P Wraight
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

Review 5.  The role of surgery in primary hyperthyroidism.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

6.  Consensus statement on management of hypothyroidism and hyperthyroidism. Registers based in general practice are essential in long term surveillance.

Authors:  J P Hill; T Pitts-Tucker
Journal:  BMJ       Date:  1996-12-07

Review 7.  Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology.

Authors:  M P Vanderpump; J A Ahlquist; J A Franklyn; R N Clayton
Journal:  BMJ       Date:  1996-08-31

8.  Long-term outcomes of treatment of hyperthyroidism in Ireland.

Authors:  A C Leary; G Grealy; T M Higgins; N Buckley; D G Barry; D Murphy; J B Ferriss
Journal:  Ir J Med Sci       Date:  1999 Jan-Mar       Impact factor: 1.568

9.  Iodine therapy for thyroidectomy patients exhibiting high thyroid-stimulating hormone values: a randomised study.

Authors:  J D Taylor; S N Radcliffe; P K Basu; P Atkins
Journal:  Ann R Coll Surg Engl       Date:  1993-05       Impact factor: 1.891

10.  Ultrasonography thyroid volume estimation in hyperthyroid patients treated with individual radioiodine dose.

Authors:  F Massaro; L Vera; M Schiavo; C Lagasio; M Caputo; M Bagnasco; F Minuto; M Giusti
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.